English
Spanish
Italian
French
Greek
Portuguese
Japanese
Danish
Dutch
Finnish
Croatian
Estonian
Filipino
Czech
Korean
Slovenian
Chinese (Simplified)
Chinese (Traditional)
Somali
Hebrew
Polish
Hindi
Hungarian
Slovak
Norwegian
Swedish
Persian
Romanian
Punjabi
Arabic
Ukrainian
Russian
Bulgarian
Indonesian
Bosnian
Afrikaans
Armenian
AlbanianA small Phase 2 trial of a new antidepressant may hold clues to the direction of Verily, the high-profile Alphabet health tech spinout that announced a new, more focused direction for its business after laying off employees last month.
Part of the goal of the research will be to recruit patients more remotely, and also to gather more data in ways that don’t require patients to come into a doctor’s office unnecessarily. The study is part of a long-standing collaboration between Verily and the drug’s maker, Otsuka Pharmaceuticals, and will aim to enroll 336 patients at 55 trial sites across the United States.
Continue to STAT+ to read the full story…
Click this link for the original source of this article.
Author: Matthew Herper and Casey Ross
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
